Safety and efficacy of autologous bone marrow aspirate concentrate injection for idiopathic male infertility: A comparative study

doi:10.5493/wjem.v15.i3.107323

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (229)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

171

Figures (1-1)

Tables (1-3)

Sum=210

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=14

Sep 20, 2025 (publication date) through Aug 16, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Exp Med. Sep 20, 2025; 15(3): 107323
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.107323

Safety and efficacy of autologous bone marrow aspirate concentrate injection for idiopathic male infertility: A comparative study

Ravi Velamoor Rangarajan, Avinash Gandi Devadas, Dhossaradhan Jayakumar Padmanapan, Naveen Jeyaraman, Swaminathan Ramasubramanian, Arulkumar Nallakumarasamy, Sathish Muthu, Madhan Jeyaraman

Ravi Velamoor Rangarajan, Avinash Gandi Devadas, Dhossaradhan Jayakumar Padmanapan, Naveen Jeyaraman, Swaminathan Ramasubramanian, Arulkumar Nallakumarasamy, Sathish Muthu, Madhan Jeyaraman, Department of Regenerative Medicine, Mother Cell Regenerative Centre, Tiruchirappalli 620017, Tamil Nadu, India

Author contributions: Ravi VR designed the research; Devadas AG and Padmanapan DJ performed data collection; Ravi VR, Ramasubramanian S, Muthu S, and Jeyaraman M finalized the manuscript; Jeyaraman N, Ramasubramanian S, Nallakumarasamy A, Muthu S, and Jeyaraman M analyzed the articles for performing review and wrote the manuscript; All of the authors read and approved the final version of the manuscript to be published.

Institutional review board statement: The study was reviewed and approved by the Ethics Committee.

Informed consent statement: All participants provided informed consent.

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Data sharing statement: All data is contained within the manuscript.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Regenerative Medicine, Mother Cell Regenerative Centre, Vayalur, Tiruchirappalli 620017, Tamil Nadu, India. madhanjeyaraman@gmail.com

Received: March 21, 2025
Revised: March 29, 2025
Accepted: April 21, 2025
Published online: September 20, 2025
Processing time: 145 Days and 4.3 Hours

Core Tip

Core Tip: This trial evaluated the safety and efficacy of autologous bone marrow aspirate concentrate (BMAC) therapy for male infertility in men aged 35–45 with severe oligospermia or azoospermia. Over six months, BMAC therapy showed a significant increase in sperm count and motility compared to pharmacotherapy and lifestyle modifications. These results highlight BMAC's potential as a regenerative medicine option for male infertility, warranting further research for clinical application.